NL-OMON51463尚未招募3 期
DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipients - DAPARHT
Oslo University Hospital0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Heart transplant recipient >= 1 year after heart transplant.
- •2. Age >= 18 years
排除标准
- •1. Contraindications to study medication.
- •2. Estimated GFR < 25 ml/min/m2
- •3. Type I diabetes
- •4. Severe liver failure (Child-Pugh*s score C)
- •5. Life expectancy reduced to < 2 years as judged by the investigator
- •6. Unresolved malignant disease
- •7. Failure to obtain written informed consent
- •8. SGL2 inhibitor treatment over the last month
- •9. Pregnancy
- •10. Breast-feeding
- •11. Woman of child-bearing potential who is not willing to use a highly
- •effective method of birth control
研究者
相似试验
进行中（未招募）
1 期
Renal protection in Heart TransplantEUCTR2021-003175-34-NOOslo University Hospital430
进行中（未招募）
1 期
Renal protection in Heart Transplantheart transplant recipients in follow-upEUCTR2021-003175-34-NLOslo University Hospital430
招募中
1 期
DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipientsKidney failure, Heart transplantCTIS2023-506486-60-01Oslo University Hospital HF220
进行中（未招募）
3 期
DAPAgliflozin for Renal Protection in Heart Transplant RecipientsHeart Transplant FailureKidney FailureNCT05321706Oslo University Hospital430
尚未招募
不适用
jDAPA-PDChronic heart failure, chronic kidney diseaseChronic heart failure, chronic kidney disease, peritoneal dialysisJPRN-jRCT1031230624Yamamoto Suguru40